More with atrial fibrillation, anticoagulants since the coming of NOAK

Forslund, T.; von Euler, M.; Johnsson, H.; Holmström, M.; Wettermark, B.ör.; Hjemdahl, P.

Lakartidningen 112

2015


ISSN/ISBN: 1652-7518
PMID: 25584610
Document Number: 684974
Since the introduction of NOAC (non-vitamin K antagonist oral anticoagulants) in 2011 as thromboprophylactic treatment for patients with atrial fibrillation, AF, the number of patients with a diagnosis of atrial fibrillation has increased markedly in our health care registers. The proportion of patients treated with warfarin or NOAC has increased from 47 % to 58 % in 2013. The use of acetylsalicylic acid in patients is decreasing rapidly in patients with AF. NOAC are mostly prescribed by specialists and are mainly used in younger patients with lower CHA2DS2-VASc scores and lower risk for renal insufficiency and bleeding.

Document emailed within 1 workday
Secure & encrypted payments